The 2025 ASCO meeting in Chicago highlighted significant cancer therapy developments, including Bristol Myers Squibb’s multibillion-dollar partnership focusing on bispecific antibodies. The conference showcased emerging modalities like dueling targeted protein degraders and antibody-drug conjugates (ADCs) that promise enhanced cancer specificity and efficacy. These advancements signal an intensifying innovation race in oncology drug development, reinforcing cancer immunotherapy and targeted treatments as pivotal strategies.